|
|
|
| United States Patent | 4645504 |
| Link to this page | http://www.wikipatents.com/4645504.html |
| Inventor(s) | Byers; Charles L. (Vacaville, CA) |
| Abstract | An implantable infection barrier seal for preventing the entry of pathogens
into an anatomical body, the body defining an exterior where pathogens
reside and an interior where pathogens are not endemic. The body interior
includes organic tissues which are not inherently exposed to the exterior.
A portion of the tissue is exposed to the exterior. The seal includes an
implantable infection barrier member that comprises of an inert,
biologically compatible material which is bonded to the exposed tissue
portion so as to shield the body interior from the pathogens residing in
the exterior. |
|
|
|
Title Information  |
|
|
|
|
|
Drawing from US Patent 4645504 |
|
|
Implantable infection barrier seal and method |
|
|
|
|
|
| Publication Date |
February 24, 1987 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title Information  |
|
|
References  |
|
|
| *references marked with an asterisk below are user-added references |
|
U.S. References |
|
|
|
|
|
|
U.S. References |
|
|
Foreign References |
|
|
|
|
|
|
Foreign References |
|
|
Other References |
|
|
|
|
|
|
Other References |
|
|
|
|
|
References  |
|
|
|
|
|
| Market Size |
|
Estimate the gross annual revenues of the relevant market
sector:
|
| | |
| |
|
|
| Market Share |
|
Estimate the percentage of the relevant market sector this invention will capture:
|
| | |
| |
|
|
| Reasonable Royalty |
|
What percentage of gross sales should the inventor or assignee be paid?
|
| | |
| |
|
|
|
Public's "Guesstimation" of Royalty Value
|
| Market Size | N/A | [No votes] | | x | Market Share | N/A | [No votes] | | x | Reasonable Royalty | N/A | [No votes] |
| | N/A | |
| |
|
|
|
|
|
|
|
|
|
|
|
|
Market Review  |
|
|
Technical Review  |
|
|
Claims  |
|
|
I claim:
1. An implantable infection barrier seal for preventing the entry of
pathogens into an anatomical body, said body defining an exterior where
pathogens reside and an interior where pathogens are not endemic, said
body interior including organic tissues, defining an opening, which are
not inherently exposed to said exterior, a portion of said tissues being
exposed to said exterior, comprising
an implantable infection barrier member shaped to fit within said opening
and comprising an inert, biologically compatible material that is capable
of being bonded directly to said exposed tissue portion so as to shield
said body interior from said pathogens residing in said exterior, wherein
said implantable infection barrier member comprises a porous ceramic
material having a pore size in the range of form 50 to 400 micrometers.
2. The implantable infection barrier seal as claimed in claim 1, wherein
said implantable infection barrier member comprises an osteogenesis
compatible material.
3. The implantable infection barrier seal as claimed in claim 1, wherein
said implantable infection barrier member comprises an epithelial
neogenesis compatible material.
4. The implantable infection barrier seal as claimed in claim 1, wherein
said implantable infection barrier member comprises calcium
hydroxy-apatite.
5. The implantable infection barrier seal as claimed in claim 1, wherein
said tissues are connective tissues comprising bone, and wherein said
implantable infection barrier member is bondable to said bone, thereby
providing said shield.
6. The implantable infection barrier seal as claimed in claim 1, wherein
said tissues are connective tissues comprise an epithelium layer, and
wherein said implantable infection barrier member is bondable to said
epithelium layer, thereby providing said shield.
7. The implantable infection barrier seal as claimed in claim 5 or 6,
wherein said implantable infection barrier member comprises an
osteogenesis compatible material.
8. The implantable infection barrier seal as claimed in claim 7, wherein
said implantable infection barrier member comprises calcium
hydroxy-apatite.
9. The implantable infection barrier seal as claimed in claim 5 or 6,
wherein said implantable infection barrier member comprises an epithelial
neogenesis compatible material.
10. The implantable infection barrier seal as claimed in claim 9, wherein
said implantable infection barrier member comprises a ceramic material.
11. The implantable infection barrier seal as claimed in claim 10, wherein
said implantable infection barrier member comprises calcium
hydroxy-apatite.
12. An implantable infection barrier seal for preventing the entry of
pathogens into an anatomical body, said body defining an exterior where
pathogens reside and an interior where pathogens are not endemic, said
body interior including a cochlea that has an orifice, said orifice having
a bone portion, and an elongated intracochlear implant having one end
adapted to be positioned inside said cochlea and another end exposed to
said exterior, comprising
an implantable infection barrier member shaped to fit within said orifice
and comprising an inert, biologically compatible material, said barrier
member being bonded to said implant and capable of being bonded to said
bone portion so as to form a shield between said cochlea and said body
exterior, thereby preventing the entry of said pathogens into said
cochlea.
13. The implantable infection barrier seal as claimed in claim 12, wherein
said cochlear orifice further includes an epithelium layer that is
positioned adjacent said portion, and wherein said implantable infection
barrier member is bondable to said epithelium layer, thereby providing an
additional barrier to said pathogens.
14. The implantable infection barrier seal as claimed in claim 12 or 13,
wherein said implantable infection barrier member is generally annular and
has an inner perimeter that is bonded to said implant and an outer
perimeter that is bondable to both said bone portion and said epithelium
layer.
15. The implantable infection barrier seal as claimed in claim 14, wherein
said implantable infection barrier member comprises an osteogenesis
compatible material.
16. The implantable infection barrier seal as claimed in claim 15, wherein
said implantable infection barrier member comprises an epithelial
neogenesis compatible material.
17. The implantable infection barrier seal as claimed in claim 16, wherein
said implantable infection barrier member comprises a porous ceramic
material having a pore size in the range of from 50 to 400 micrometers.
18. The implantable infection barrier seal as claimed in claim 17, wherein
said implantable infection barrier member comprises calcium
hydroxy-apatite.
19. The implantable infection barrier seal as claimed in claim 18, further
comprising
means comprising a paste-like composition of chips of said bone portion for
enhancing said bonding of said implantable infection barrier member to
said bone portion.
20. A method of creating an implantable infection barrier seal to prevent
the entry of pathogens into an anatomical body, said body defining an
exterior where pathogens reside and an interior where pathogens are not
endemic, said body interior including organic tissues which are not
inherently exposed to said exterior, comprising
exposing a portion of said tissues to said exterior,
preparing said tissue portion with an opening shaped to receive said
implantable infection barrier seal,
forming said implantable infection barrier seal to include an implantable
infection barrier member that comprises an inert, biologically compatible
material which is capable of fitting within said opening and bonding to
said exposed tissue portion directly, wherein said implantable infection
barrier member comprises a porous ceramic material having a pore size in
the range of from 50 to 400 micrometers and
positioning said implantable infection barrier member adjacent to said
exposed tissue portion so as to bond said member to said exposed tissue
portion directly, thereby shielding said body interior from said pathogens
residing in said exterior.
21. The method as claimed in claim 20, wherein said implantable infection
barrier member comprises an osteogenesis compatible material.
22. The method as claimed in claim 20, wherein said implantable infection
barrier member comprises an epithelial neogenesis compatible material.
23. The method as claimed in 20, wherein said implantable infection barrier
member comprises calcium hydroxy-apatite.
24. A method of creating an implantable infection barrier seal to prevent
the entry of pathogens into an anatomical body, said body defining an
exterior where pathogens reside and an interior where pathogens are not
endemic, said body interior including a cochlea that has an orifice, said
orifice having a bone portion, said orifice being adapted to receive an
elongated intracochlear implant one end of which is positioned inside said
cochlea and another end which is exposed to said exterior, comprising
exposing a portion of said orifice to said exterior,
preparing said exposed orifice portion to receive said implantable
infection barrier seal,
providing said implantable infection barrier seal, said seal including an
implantable infection barrier member that comprises of an inert,
biologically compatible material which is capable of bonding to said
exposed orifice portion, to provide a shield between said cochlea and said
body exterior, and
positioning said implantable infection barrier member adjacent to said
exposed orifice portion so as to enhance said bonding of said member with
said exposed orifice portion, thereby shielding said cochlea from said
pathogens residing in said exterior.
25. The method as claimed in claim 24, wherein said cochlear orifice
further includes an epithelium layer that is positioned adjacent said bone
portion, and wherein said implantable infection barrier member is bonded
to said epithelium layer, thereby providing an additional barrier to said
pathogens.
26. The method as claimed in claim 24 or 25, wherein said implantable
infection barrier member is a generally annular device having an inner
perimeter that is bonded to said elogated implant and an outer perimeter
that is bonded to both said bone portion and said epithelium layer.
27. The method as claimed in claim 26, wherein said implantable infection
barrier member comprises an osteogenesis compatible material.
28. The method as claimed in claim 27, wherein said implantable infection
barrier member comprises an epithelial neogenesis compatible material.
29. The method as claimed in claim 28, wherein said implantable infection
barrier member comprises a ceramic material.
30. The method as claimed in claim 29, wherein said implantable infection
barrier member comprises calcium hydroxy-apatite.
31. The method as claimed in claim 30, further comprising
providing a paste-like composition of chips of said bone portion to enhance
said bonding of said implantable infection barrier member with said bone
portion, and
positioning said composition contiguous with said member to as to enhance
said bonding. |
|
|
|
|
Claims  |
|
|
Description  |
|
|
TECHNICAL FIELD
This invention relates to implantable prostheses, and more particularly, to
an implantable infection barrier seal.
BACKGROUND ART
With the advent of implantable prostheses, a new type of infection is
becoming prevalent. That new type of infection is generally categorized as
prostheses-enhanced infection, i.e., infection enhanced by the presence of
such implantable prostheses. Since most implantable prostheses are
manufactured from materials which living tissue does not bond to, a
fibrous lining or sheath of connective tissue invariably forms around such
an implant. In addition, many implantations require the piercing of the
epithelium layer, the anatomical bacterial barrier or shield. Coupled with
the piercing of the epithelium, the fibrous sheath or lining, which does
not adhere to the implant, tends to leave an open channel between the
implant and itself, an ideal pathway for invading pathogens. To prevent
any potential infection, antibiotics must be used. In many instances,
however, continuing use of antibiotics may be impractical or impossible
after the original application of such antibiotics. For example,
antibiotics are generally used at the initial implant stages of implanting
an intracochlear device. After such a device is in position, application
of such antibiotics is not practical, e.g., applying antibotics to the
middle ear region. Moreover, continued chronic use of antibiotics may be
undesirable. Further, once infection has set in around a foreign body such
as an implant, antibiotics are ineffective in combatting the infection
since the infection will remain chronic until the foreign body is removed.
An implantable infection barrier seal is, therefore, desirable.
The ideal implantable infection barrier seal should be capable of providing
a permanent barrier to infectious pathogens. It should be capable of
eliminating passageways for such pathogens. In addition, such an
implantable seal should be capable of minimizing or eliminating the need
for the continued use of antibiotics.
DISCLOSURE OF THE INVENTION
In view of the prior art, it is a major object of the present invention to
provide an implantable infection barrier seal that forms a barrier against
invading pathogens such as the elimination of passageways for such
pathogens.
It is another object of the present invention to provide an implantable
infection barrier seal that minimizes or eliminates the necessity of using
antibiotics.
It is a further object of the present invention to provide an implantable
infection barrier seal that is capable of functioning as an anchor for a
prothesis such that the prothesis is not easily dislodged when such
dislodgment could compromise the effectiveness of the prothesis or promote
the entry of pathogens.
In order to accomplish the above and still further objects, the present
invention provides an implantable infection barrier seal for preventing
the entry of pathogens into an anatomical body, the body defining an
exterior where pathogens reside and an interior where pathogens are not
endemic. The body interior includes organic tissues which are not
inherently exposed to the exterior. A portion of the tissues is exposed to
the exterior. The seal includes an implantable infection barrier member
that comprises an inert, biologically compatible material which is bonded
to the exposed tissue portion so as to shield the body interior from the
pathogens residing in the exterior.
Other objects, features and advantages of the present invention will appear
from the following detailed description of the best mode of a preferred
embodiment, taken together with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a partial, enlarged cross section view of the implantable
infection barrier seal of the present invention;
FIG. 2 is a partial, enlarged cross section view of another embodiment of
the implantable infection barrier seal of the present invention; and
FIG. 3 is a partial, enlarged cross section view of a further embodiment of
the implantable infection barrier seal of FIG. 1.
BEST MODE FOR CARRYING OUT THE INVENTION
Referring to FIG. 1, there is shown an implantable prosthesis, designated
12. In this particular instance, prosthesis 12 is an intracochlear device
that is implanted within a cochlea 14. As illustrated, cochlea 14 has a
round window 16, scala vestibuli 18 and scala tympani 20. Round window 16
is a bony opening 22 with an epithelium layer 24. Intracochlear device 12
has a tubular member 26 that envelops a bundle of elongated electrode
wires 28. Intracochlear device 12 enters cochlea 14 at its round window
16. Since intracochlear device 12 is manufactured from a material that is
foreign, albeit inert, to the cochlear tissues, a fibrous lining or sheath
invariably grows and envelops device 12, not shown. The phenomenon of
fibrous growth around a foreign object is well within the knowledge of one
skilled in the art. Since the fibrous sheath does not bond with device 12,
a passageway or channel develops between it and device 12, also not shown.
The resulting passageway between device 12 and the sheath is an ideal
conduit for the entry of pathogens from the exterior of the body. Although
the intracochlear device 12 is implanted with a topical application of
antibiotics, it is not possible to apply additional antibiotics after the
implantation. Thus, developing a middle ear infection is possible in
anyone, especially children. Middle ear infections could evolve into
dangerous, and even life-threatening infections, since the cochlea is in
direct communication with the brain and the central nervous system.
Accordingly, an implantable infection barrier seal of the present invention
is provided, generally designated 30. Infection seal 30 is manufactured
from an inert, biologically compatible material, a ceramic material in the
preferred embodiment. The ceramic material of the preferred embodiment, an
osteogenesis compatible material, is calcium hydroxy-apatite, marketed
under the trademark CERAVITAL, registered to Xomed, Inc. of Florida. Seal
30 in the preferred embodiment is a porous material that is capable of
bonding with connective tissues, especially osteogenic tissue. The pore
size of the material should be of a range from 50 to 400 micrometers.
More particularly, infection seal 30 in the preferred embodiment is an
annular device that is mounted on intracochlear device 12. An inner
perimeter 32 of annular seal 30 is bonded to the polymeric tubular body 26
of intracochlear device 12. An outer perimeter 34 of annular seal 30 is in
turn placed contiguous to bone 22 of round window 16. Since the material
of annular seal 30 is compatible with bone 22 of round window 16, annular
device 30 quickly receives new growth of bone 22 and bonds therewith. In
addition, epilithium 24 also grows onto annular seal 30 and develops a
fibrous tissue bond. Such bonding eliminates potential pathogen
passageways between intracochlear device 12 and bone 22 of round window
16.
In addition to the prevention of infection, annular device 30 in this
embodiment provides a mechanical support or anchor for intracochlear
device 12. Whereas prior art intracochlear devices are not anchored,
resulting in slippage and movement, intracochlear device 12 in the
preferred embodiment is secured to bone 22 of round window 16 by annular
seal 30. Dislodgment of device 12 such as slippage and movement could
reduce the prosthetic value of such an implant. In addition, dislodgment
of device 12 could open a passageway such that external pathogens could
enter into the interior of the body.
In use, a conventional intracochlear device 12 is selected. Device 12 has a
length of approximately 70 millimeters, with a 25-millimeter portion of
which is disposed inside cochlea 14, and a diameter of approximately one
millimeter. The bundle of electrode wires 28 is encased within elongated
tube 26 which is manufactured from a silicon elastomer, generally referred
to as silastic. An annular implantable inflection barrier seal 30 is then
selected. Seal 30 in the preferred embodiment has dimensions which are
appropriate for the application. Inner perimeter 32 of seal 30 is first
conventionally bonded to silastic casing 26 of intracochlear device 12. A
conventional silastic adhesive is used for this purpose. For bonding
annular seal 30 to round window 16, portions of round window 16 are
removed to expose bony portion 22. A membrane, not shown, that covers the
opening of round window 16 is removed. In addition, appropriate portions
of epithelium layer 24 are either removed or opened. Portions of infection
seal 30 adjacent its outer perimeter 34 are placed contiguous to bone 22
of round window 16. This procedure is a conventional technique readily
known to one skilled in the art. Thus positioned, the pores of seal 30,
generally in the range of 50 to 400 micrometers in the preferred
embodiment, permit the growth of bone tissues thereon, producing a
permanent bond between seal 30 and bone 22 of round window 16. In
addition, epithelium 24 also forms bonds with annular seal 30. The
resultant permanent bond, thereby, eliminates the possibility of
passageways which may enhance the entry of pathogens from the exterior of
the body. Moreover, the particular use of seal 30 in the preferred
embodiment creates an anchor for intracochlear device 12 such that
slippage and movement of device 12 is minimized or eliminated.
As best shown in FIG. 2, an alternative embodiment of infection seal 30 is
illustrated. In this embodiment, an implantable infection barrier seal 130
is provided. Since many elements in the alternative embodiment are similar
to elements of the preferred embodiment, a numeral "1" is added to the
numerals which designated corresponding elements of the preferred
embodiment. For example, the infection seal of the alternative embodiment
is designated 130.
Infection seal 130 in the alternative embodiment is configured as a
tissue-integrated percutaneous connector. Such a connector is generally
implanted in order to provide means to activate instruments and devices
which are implanted deeper inside a body. Thus, a plurality of electrical
connecting ports 150 are provided which in turn are connected to a
plurality of electrical wires 128. Electrical wires 128, connected to an
implanted device, not shown, is encased with tubular cable 126.
In use, an appropriate amount of bone 122 is removed such that seal 130 may
be placed therein. In addition, an appropriate conduit is formed such that
it is capable of receiving cable 126. In due course, bonding would occur
between seal 130 and bone 122 and between seal 130 and epithelium layer
124. The external portion of epithelium 124, generally referred to as
skin, is designated 152. Whereas prior art implants could not form a seal
between an implant and the bone, pathogens from the exterior would likely
to travel between the implant and the bone such that infections would
occur. Even more invidious is when pathogens would travel along the
conduit of cable 126 and infect an internal region deep within the body.
FIG. 3 illustrates a further alternative embodiment in which a paste-like
composition 40 of autologous bone chips is positioned at the junction
between seal 30 and bone 22 of round window 16. Composition 40 is
generally referred to as pate. Pate 40 enhances the bonding of seal 30
with bone 22. This procedure is generally necessary to fill any gap that
may exist between bone 22 and an implant since it is generally difficult
to provide a site on bone 22 that exactly matches the dimensions of an
implant. In addition, pate 40 may be used at a site on the body where bone
is required, but absent. Thus, pate 40 is used to provide the growth of a
bony site. These procedures are also conventional techniques readily known
to one skilled in the art. Although bone 22 and pate 40 are illustrated as
two separate entities, they will eventually evolve into a single entity,
bone 22, after the bone chips of pate 40 grow into and merge with bone 22.
It will be apparent to those skilled in the art that various modifications
may be made within the spirit of the invention and the scope of the
appended claims. For example, although only connective tissues such as
bone and epithelium have been described, the human body nonetheless
includes other tissues positioned adjacent to or interlaid between these
enumerated tissues and those other tissues may bond with the infection
seal.
* * * * *
|
|
|
|
|
Description  |
|
|
|
|
|